The estimated Net Worth of Aaron Ren is at least $573 Thousand dollars as of 18 November 2020. Aaron Ren owns over 2,000 units of Viela Bio stock worth over $2,840 and over the last 5 years he sold VIE stock worth over $0. In addition, he makes $570,386 as Vice President - Head of Business Development and Operations at Viela Bio.
Sign up
Aaron Ren VIE stock SEC Form 4 insiders trading
Aaron has made over 1 trades of the Viela Bio stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 2,000 units of VIE stock worth $5,680 on 18 November 2020.
The largest trade he's ever made was exercising 2,000 units of Viela Bio stock on 18 November 2020 worth over $5,680. On average, Aaron trades about 1,000 units every 0 days since 2020. As of 18 November 2020 he still owns at least 113,613 units of Viela Bio stock.
You can see the complete history of Aaron Ren stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Aaron Ren biography
Dr. Aaron Ren Ph.D. serves as Vice President - Head of Business Development and Operations of the Company. He is managing business development, quality, information technology, procurement and contracts functions. Prior to joining us, from March 2016 to February 2018, Dr. Ren was with MedImmune, as a Director within BioPharmaceutical Development group and as MedImmune China Lead, managing the company’s research and development initiatives for China. From February 2014 to February 2016, Dr. Ren was an Associate Director within MedImmune’s Partnering and Strategy group and led multiple business development transactions. Before joining MedImmune, Dr. Ren was a management consultant with McKinsey and Company from September 2011 to January 2014. Dr. Ren also held various roles with increasing responsibilities respectively with SR One, Schering-Plough, and Abbott Labs, where he started his career as a senior clinical pharmacologist for Humira. Dr. Ren received his B.S. in Cell Biology and Genetics from Peking University in China, M.B.A. with honors in Finance and Healthcare Management from the Wharton School at the University of Pennsylvania and a Ph.D. in Pharmaceutics from the University of Washington, during which he was an Eli Lilly Fellow.
What is the salary of Aaron Ren?
As the Vice President - Head of Business Development and Operations of Viela Bio, the total compensation of Aaron Ren at Viela Bio is $570,386. There are 3 executives at Viela Bio getting paid more, with Zhengbin Yao having the highest compensation of $2,747,550.
How old is Aaron Ren?
Aaron Ren is 43, he's been the Vice President - Head of Business Development and Operations of Viela Bio since 2018. There are 9 older and 2 younger executives at Viela Bio. The oldest executive at Viela Bio, Inc. is Chris Nolet, 63, who is the Independent Director.
What's Aaron Ren's mailing address?
Aaron's mailing address filed with the SEC is C/O VIELA BIO, INC.,, ONE MEDIMMUNE WAY, FIRST FLOOR, AREA TWO, GAITHERSBURG, MD, 20878.
Insiders trading at Viela Bio
Over the last 5 years, insiders at Viela Bio have traded over $58,712,400 worth of Viela Bio stock and bought 1,261,091 units worth $24,062,867 . The most active insiders traders include Andreas Wicki, Xiaomeng Tong, and Plc Astra Zeneca Uk Ltd Ast.... On average, Viela Bio executives and independent directors trade stock every 41 days with the average trade being worth of $6,348. The most recent stock trade was executed by Aaron Ren on 18 November 2020, trading 2,000 units of VIE stock currently worth $5,680.
What does Viela Bio do?
Viela Bio, Inc., a clinical-stage biotechnology company, engages in the research and development of treatments for severe inflammation and autoimmune diseases in the United States. The company's lead product candidate is inebilizumab, a humanized monoclonal antibody for neuromyelitis optica spectrum disorder, kidney transplant desensitization, myasthenia gravis, and IgG4-related diseases. It is also developing VIB4920 for kidney transplantation rejection and sjögren's syndrome; and VIB7734 for cutaneous lupus erythematosus. Viela Bio, Inc. has a strategic collaboration with Mitsubishi Tanabe Pharma Corporation to develop and commercialize inebilizumab for autoimmune diseases in Japan, Thailand, South Korea, Indonesia, Vietnam, Malaysia, the Philippines, Singapore, and Taiwan. The company was founded in 2017 and is headquartered in Gaithersburg, Maryland.
What does Viela Bio's logo look like?
Complete history of Aaron Ren stock trades at Viela Bio
Viela Bio executives and stock owners
Viela Bio executives and other stock owners filed with the SEC include:
-
Zhengbin Yao,
Chairman of the Board, President, Chief Executive Officer -
Jorn Drappa,
Chief Medical Officer, Head of Research and Development -
Mitchell Chan,
Chief Financial Officer -
Aaron Ren,
Vice President - Head of Business Development and Operations -
Chris Nolet,
Independent Director -
Edward Hu,
Independent Director -
Yanling Cao,
Director -
Chad Rubin,
IR Contact Officer -
Andreas Wicki,
Independent Director -
Tyrell Rivers,
Independent Director -
Rachelle Jacques,
Independent Director -
Sean Tong,
Director -
Jim Kastenmayer,
General Counsel, Secretary -
William Ragatz,
Vice President - Head of Commercial -
Xiaomeng Tong,
Director -
Plc Astra Zeneca Uk Ltd Ast...,
-
Meadow Ltd Boundless,
10% owner -
James Paul Kastenmayer,
General Counsel -
Meadow Ltd Boyu Capital Fun...,